Generian

Generian is a small United States-based company operating in the sphere of drug discovery. Headquartered in Pittsburgh, Pennsylvania, Generian is a privately held company with 4 employees and generates an annual revenue of $2.5 million. Generian focuses on developing small molecule drugs to address limitations associated with biologics, aiming to enhance patient convenience and accessibility. Their unique drug discovery approach allows for screening of proteins within their natural cellular environment, potentially unlocking treatments for previously undruggable targets. Generian utilizes highly translational phenotypic screening to efficiently identify target binders, leading to more precise and effective drug development. The company actively pursues internal programs targeting clinically validated proteins like FcRn and IL-4r alpha. Additionally, Generian collaborates with pharmaceutical company Astellas to explore novel targets, expanding their research scope and potential therapeutic applications. For further information about Generian's innovative drug discovery pipeline, interested parties can contact the company via email at [email protected].